Skip to main content
TipRanks
Go Ultimate75% OFF

SMS Pharmaceuticals Limited (SMSPHARMA) AI Stock Analysis

3 Followers
IN:SMSPHARMA

SMS Pharmaceuticals Limited

(NSE:SMSPHARMA)

Select Model
Rating:62Neutral
Price Target:INR 539.00â–²(10.76% Upside)
Action:reiterated
Date:09/19/26

The overall score of 62 reflects a company with a solid financial foundation and strong positive price momentum, offset by significant concerns. The primary strength is the robust balance sheet and bullish technical trend, with the stock trading above all key moving averages. However, the major risks are persistently weak cash flow generation and a high valuation (P/E of 39.4), which leaves little room for error. The company is in an investment phase, and its success hinges on translating spending into improved cash flows and margins.

Positive Factors
Improving Balance SheetLower debt alongside a larger equity base improves financial resilience and reduces balance-sheet pressure. This gives SMS Pharmaceuticals more flexibility to fund operations and strategic investment, while making the company better positioned to withstand earnings volatility over the next several quarters.
Negative Factors
Weak Free Cash FlowPersistent negative free cash flow means reported earnings are not consistently converting into cash available for reinvestment, debt reduction, or distributions. The sharp FY2026 deterioration raises questions about the cash demands of operations and capital spending, limiting financial flexibility.

SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%80%100%IN:SMSPHARMA+71.68%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 45.51B
Dividend Yield
0.08%
Average Volume (3M)
39.71K
Price to Earnings (P/E)
38.5
Beta (1Y)
1.13
Revenue Growth
12.96%
EPS Growth
32.16%
Country
India
Employees
1,617
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - General

SMS Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of AP...

SMS Pharmaceuticals Limited Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong (Score 85) with low debt-to-equity of 0.25, but cash flow is weak (Score 42) with persistent negative free cash flow. The income statement (Score 62) shows moderate growth and profitability recovery, though margin volatility and a past loss are concerns. The overall financial picture is stable but constrained by poor cash conversion.

Income Statement

62Positive

Balance Sheet

85Very Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.73B8.87B7.83B7.09B5.22B5.15B
Gross Profit2.73B1.75B1.45B2.11B1.29B1.81B
EBITDA1.97B1.71B1.45B1.18B593.89M1.20B
Net Income1.17B1.02B691.36M498.26M-70.59M622.20M
Balance Sheet
Total Assets14.61B13.62B11.53B10.34B8.80B8.60B
Cash, Cash Equivalents and Short-Term Investments363.13M460.75M415.86M361.16M73.78M465.83M
Total Debt3.49B3.65B3.11B2.81B2.54B2.63B
Total Liabilities6.18B5.77B5.13B4.98B4.19B3.89B
Stockholders Equity8.43B7.86B6.40B5.36B4.61B4.70B
Cash Flow
Free Cash Flow0-926.46M-588.57M-20.35M-74.71M129.86M
Operating Cash Flow0379.12M645.23M501.25M224.50M402.34M
Investing Cash Flow0-1.32B-1.24B-520.72M-296.86M-271.53M
Financing Cash Flow0981.46M644.32M306.79M-319.69M-69.21M

SMS Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price486.65

Price Trends

50DMA458.58Positive
100DMA419.30Positive
200DMA398.96Positive

Market Momentum

MACD15.94Positive
RSI51.88Neutral
STOCH22.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Positive. The current price of 486.65 is above the 20-day moving average (MA) of 482.48, above the 50-day MA of 458.58, and above the 200-day MA of 398.96, indicating a bullish trend. The MACD of 15.94 indicates Positive momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 22.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SMSPHARMA.

SMS Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SMSPHARMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:GLANDIN:GLAND76OutperformINR 536.16B43.32―0.62%21.90%56.28%
IN:MARKSANSIN:MARKSANS69NeutralINR 138.58B24.77―0.29%24.20%59.18%
IN:SENORESIN:SENORES63NeutralINR 52.45B37.35――39.71%53.21%
IN:SMSPHARMAIN:SMSPHARMA62NeutralINR 45.58B38.49―0.08%12.96%32.16%
IN:KOPRANIN:KOPRAN60NeutralINR 13.22B33.50―1.10%34.11%123.11%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:NGLFINEIN:NGLFINE46NeutralINR 17.67B27.53―0.06%40.66%208.52%

* General Sector Average

Performance Comparison

0%50%100%150%IN:SMSPHARMAIN:GLANDIN:KOPRANIN:MARKSANSIN:NGLFINEIN:SENORESDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SMSPHARMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SMSPHARMASMS Pharmaceuticals Limited486.65203.8972.11%
IN:GLANDGland Pharma Ltd.3249.251490.7684.77%
IN:KOPRANKopran Limited273.50142.72109.13%
IN:MARKSANSMarksans Pharma Limited305.80117.2762.20%
IN:NGLFINENGL Fine-Chem Ltd.2859.951506.61111.33%
IN:SENORESSenores Pharmaceuticals Ltd.1138.85347.1043.84%

SMS Pharmaceuticals Limited Corporate Events

SMS Pharmaceuticals wins tax appeal; Rs 45.63 crore demand vacated

Oct 31, 2026

SMS Pharmaceuticals Limited has announced that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has allowed its appeal against an income tax assessment order for Assessment Year 2023-24. The appellate order under Section 250...

SMS Pharmaceuticals’ tax appeal dismissed; reduced demand upheld

Oct 31, 2026

SMS Pharmaceuticals Limited has disclosed that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has dismissed the company’s appeal against an earlier assessment order for the 2018-19 financial year. The case stems from a tax...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026